ArticleOncotarget2015
Targeting chemotherapy-induced PTX3 in tumor stroma to prevent the progression of drug-resistant cancers.
Article in Oncotarget, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 73 citations in OpenAlex.
- Human umbilical cord mesenchymal stem cell-derived exosomes inhibit inflammation and fibrotic scar formation after intracerebral hemorrhage.Molecular and cellular biochemistry · 2025Article
- Basic biology and roles of CEBPD in cardiovascular disease.Cell death discovery · 2025Review
- The feasibility of targeting macrophage for disease treatment: roles of CEBPD.Frontiers in immunology · 2025Review
- Hypoxia Abrogates Tumor-Suppressive Activities of C/EBPδ in Pancreatic Cancer.International journal of molecular sciences · 2024Article
- Inactivation of pentraxin 3 suppresses M2-like macrophage activity and immunosuppression in colon cancer.Journal of biomedical science · 2024Article
- The Role of Pentraxin 3 in Gastrointestinal Cancers.Cancers · 2023Review
- Deletion of the mRNA stability factorNAR cancer · 2023Article
- Astrocytic Cebpd Regulates Pentraxin 3 Expression to Promote Fibrotic Scar Formation After Spinal Cord Injury.Molecular neurobiology · 2023Article
- Beyond direct killing-novel cellular immunotherapeutic strategies to reshape the tumor microenvironment.Seminars in immunopathology · 2023Review
- The biological impacts of CEBPD on urothelial carcinoma development and progression.Frontiers in oncology · 2023Review
- STAT3 Activates the Pentraxin 3 Gene in Chronic Lymphocytic Leukemia Cells.Journal of immunology (Baltimore, Md. : 1950) · 2022Article
- Macrophage C/EBPδ Drives Gemcitabine, but Not 5-FU or Paclitaxel, Resistance of Pancreatic Cancer Cells in a Deoxycytidine-Dependent Manner.Biomedicines · 2022Article
- Disruption of the pentraxin 3/CD44 interaction as an efficient therapy for triple-negative breast cancers.Clinical and translational medicine · 2022Article
- Pentraxin 3 Facilitates Shrimp-Allergic Responses in IgE-Activated Mast Cells.Journal of immunology research · 2022Article
- Integrated single-cell and bulk RNA sequencing analysis identifies a cancer associated fibroblast-related signature for predicting prognosis and therapeutic responses in colorectal cancer.Cancer cell international · 2021Article
- Non-Tumor CCAAT/Enhancer-Binding Protein Delta Potentiates Tumor Cell Extravasation and Pancreatic Cancer Metastasis Formation.Biomolecules · 2021Article
- Fibroblast CEBPD/SDF4 axis in response to chemotherapy-induced angiogenesis through CXCR4.Cell death discovery · 2021Article
- Chemotherapy-Induced Upregulation of Small Extracellular Vesicle-Associated PTX3 Accelerates Breast Cancer Metastasis.Cancer research · 2021Article
- SH3RF3 promotes breast cancer stem-like properties via JNK activation and PTX3 upregulation.Nature communications · 2020Article
- Silencing of PTX3 alleviates LPS-induced inflammatory pain by regulating TLR4/NF-κB signaling pathway in mice.Bioscience reports · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The tumor microenvironment has been suggested to participate in tumorigenesis, but the nature of the communication between cancer cells and the microenvironment, especially in response to anticancer drugs, remains obscure. We determined that activation of the CCAAT/enhancer binding protein delta (CEBPD) response to Cisplatin and 5-Fluorouracil in cancer-associated macrophages and fibroblasts contributed to the metastasis, invasion, acquired chemoresistance and stemness of cancer cells by in vitro and in vivo assays. Specifically, reporter and in vivo DNA binding assays were used to determine that Pentraxin 3 (PTX3) is a CEBPD responsive gene and serves a protumor role upon anticancer drug treatment. Finally, a PTX3 peptide inhibitor RI37 was developed and assessed the antitumor effects by in vivo assays. RI37 could function as a promising inhibitor for preventing cancer progression and the metastasis, invasion and progression of drug-resistant cancers. The identification of PTX3 provided a new insight in the interaction between host and tumor and the RI37 peptide showed a great opportunity to largely reduce the risk of invasion and metastasis of cancer and drug-resistant cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.